Skip to main content
SpringerLink
Log in

The staging of malignant melanoma and the florida melanoma trial

  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Lymphatic mapping and sentinel lymph node (SLN) biopsy have changed the standard of care for patients with malignant melanoma, by providing a less morbid procedure to obtain the nodal staging information that is critical for therapeutic decisions. Detailed examination of the SLN identifies patients who have an increased risk for recurrence and death. Patients whose melanoma is upstaged with very sensitive assays based on reverse transcriptase polymerase chain reaction technology are better targeted for clinical trials or surgical or adjuvant therapies. In the future, melanoma may be “ultrastaged” by examining the SLNs, peripheral blood, and bone marrow. This may improve identification of patients who are surgically cured of their disease and therefore can be spared the side effects of more radical surgery or the toxicities of adjuvant therapy. The lymphatic mapping procedure is the most accurate way to determine the tumor status of the regional lymph nodes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma.Cancer 1993;71:2995–3005.

    Article  PubMed  CAS  Google Scholar 

  2. Balch CM, Soong SJ, Gershenwald J et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the new AJCC melanoma staging system.J Clin Oncol 2001;19:3622–34.

    PubMed  CAS  Google Scholar 

  3. Cochran AJ, Wen DR, Morton DL. Occult tumor cells in lymph nodes of patients with pathological stage I melanoma: an immunohistological study.Am J Surg Pathol 1988;12:612–8.

    Article  PubMed  CAS  Google Scholar 

  4. Morton DL, Wen D-R, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma.Arch Surg 1992;127:392–9.

    PubMed  CAS  Google Scholar 

  5. Dessureault S, Soong SJ, Ross MI, et al. Improved staging of node-negative patients with intermediate to thick melanomas (>1.0 mm) with the use of lymphatic mapping and sentinel lymph node biopsy.Ann Surg Oncol 2001;8:749–51.

    Article  Google Scholar 

  6. Heller R, Wasselle J, Becker J, et al. The detection of submicroscopic lymph node metastases in patients with malignant melanoma.Arch Surg 1991;126:1455–60.

    PubMed  CAS  Google Scholar 

  7. Heller R, Becker J, Wasselle J, et al. Detection of occult lymph node metastases in malignant melanoma.Ann Plastic Surg 1992; 28:74–7.

    Article  CAS  Google Scholar 

  8. Heller R, King B, Baekey P, et al. The identification of submicroscopic lymph node metastases in patients with malignant melanoma.Semin Surg Oncol 1993;9:285–9.

    PubMed  CAS  Google Scholar 

  9. Wang X, Heller R, Van Voorhis N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma.Ann Surg 1994;220:768–75.

    Article  PubMed  CAS  Google Scholar 

  10. Cho KH, Hashimoto K, Taniguchi Y, et al. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits.Cancer 1990;66:765–71.

    Article  PubMed  CAS  Google Scholar 

  11. Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome.JAMA 1998;280:1410–5.

    Article  PubMed  CAS  Google Scholar 

  12. Smith B, Selby P, Southgate J, et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction.Lancet 1991;338:1227–9.

    Article  PubMed  CAS  Google Scholar 

  13. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group EST 1684 Trial.J Clin Oncol 1996;14:7–17.

    PubMed  CAS  Google Scholar 

  14. Li W, Stall A, Shivers SC, et al. Clinical relevance of molecular staging for melanomal.Ann Surg 2000;231:795–803.

    Article  PubMed  CAS  Google Scholar 

  15. Shivers S, Hoffman S, Lin J, et al. Low specificity for detection of sentinel node micrometastases by a nested RT-PCR assay for tyrosinase in melanoma patients [abstract]. Paper presented at: Proceedings of the 54th Annual Cancer Symposium, Society of Surgical Oncology; March 15–18, 2001; Washington, DC.

  16. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs.N Engl J Med 1977;297:627–31.

    Article  PubMed  CAS  Google Scholar 

  17. Sim FH, Taylor WF, Pritchard DJ, et al. Lymphadenectomy in the management of stage I malignant melanoma: A prospective randomized study.Mayo Clin Proc 1986;61:697–701.

    PubMed  CAS  Google Scholar 

  18. Kirkwood J, Ibrahim JG, Sondak V, et al. High- and low-dose interferon alfa 2-b in high-risk melanoma: first analysis of Intergroup Trial E1690/S9111/C9190.J Clin Oncol 2000;18:2444–58.

    PubMed  CAS  Google Scholar 

  19. Kirkwood JM, Ibrahim J, Sosman JA, et al. High- and low-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with GM2-KLH/QS-21 vaccine in patients with resected Stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.J Clin Oncol 2001;19:2370–80.

    PubMed  CAS  Google Scholar 

  20. Mellado B, Colomer D, Castel T, et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis.J Clin Oncol 1996;14:2091–7.

    PubMed  CAS  Google Scholar 

  21. McMasters KM, Edwards, M, Ross M, et al. Frequency of nonsentinel lymph node metastases in melanoma [abstract]. Paper presented at: Proceedings of the 54th Annual Cancer Symposium, Society of Surgical Oncology; March 15–18, 2001; Washington, DC.

  22. Bieligk SC, Ghossein R, Bhattacharya S, et al. Detection of tyrosinase mRNA by reverse transcription polymerase chain reaction in melanoma sentinel nodes.Ann Surg Oncol 1999;6:225–6.

    Article  Google Scholar 

  23. Bostick PJ, Morton DL, Turner RR, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients.J Clin Oncol 1999;17:3238–44.

    PubMed  CAS  Google Scholar 

  24. Goydos JS, Ravikumar TS, Germino FJ, et al. Minimally invasive stating of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction.J Am Coll Surg 1998;187:182–8.

    Article  PubMed  CAS  Google Scholar 

  25. Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases.J Clin Oncol 1999; 17:2562–71.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cutaneous Oncology Program, Lakeland Regional Cancer Center, 3525 Lakeland Hills Blvd., P. O. Box 91057, 33804-1057, Lakeland, FL

    Douglas S. Reintgen MD, James W. Jakub MD, Solange Pendas MD, Gray Swor MD, Rosemary Giuliano ARNP, MSN & Steve Shivers PhD

Authors
  1. Douglas S. Reintgen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James W. Jakub MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Solange Pendas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gray Swor MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rosemary Giuliano ARNP, MSN
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Steve Shivers PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas S. Reintgen MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reintgen, D.S., Jakub, J.W., Pendas, S. et al. The staging of malignant melanoma and the florida melanoma trial. Annals of Surgical Oncology 11 (Suppl 3), 186S–191S (2004). https://doi.org/10.1007/BF02523626

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02523626

Key Words

Search

Navigation